Q-omics provides the consensus-scored F11 profile across patient tissues and cancer cell-line models. F11 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, F11 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, F11 protein abundance shows 25,556 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where F11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for F11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes F11 survival associations across molecular data types. F11 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible F11 RNA expression–survival associations across cancer types. High F11 expression shows unfavorable associations in MESO and THCA, but favorable associations in KIRC, LIHC, KIRP and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for F11 RNA expression.
This table summarizes F11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for F11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. F11 shows lower tumor expression in KIRC, KIRP, LUAD, KICH, LUSC and CHOL. The KIRC box plot shows higher F11 RNA expression in normal versus tumor tissue (log2 FC = −3.812, t-test p < 0.001).
This table shows molecular features associated with F11 in patient tissues and cancer cell lines. In patient samples, F11 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, F11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
